High quality clinical data is needed in your study analysis to avoid difficulties and delays as you seek approval with your regulatory submission. Do not let poor quality data slow down the pace of your trial.
This is more critical as the pharmaceutical industry unites to defeat the COVID-19 global pandemic. Governments want to bring any vaccine or effective treatments to market as quickly as possible, and high quality clinical data will bring efficiencies to trials and faster regulatory submissions to support that aim.
We offer expertise via statistical support in designing COVID-19 trials and in collecting, analysing and reporting trial data.
Quanticate's experience in respiratory trial data has seen countless regulatory approvals.
We have undertaken vaccine and antiviral trials and have proven to experience in this therapeutic area.
Our years of experience have led us to be the preferred statistical and programming vendor for one of the top 5 pharmaceutical companies.
This relationship has been long-lasting, covering their needs across many of our service offerings, across numerous therapeutic areas, including respiratory. We have the capability of working and adapting to any requirements, and can do so for any therapeutic area.
We support statistical elements of protocol development from the early stages in order to design rapid and effective trials that will meet the required outcomes to gain regulatory approval.